DrugPatentWatch Database Preview
Drugs in Development Information for Papaverine
Drug Development Status for Papaverine: Sponsors, patents, clinical trial progress
Papaverine is an investigational drug.
There have been 13 clinical trials for Papaverine.
The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2019.
The most common disease conditions in clinical trials are Erectile Dysfunction, Enuresis, and Schizophrenia. The leading clinical trial sponsors are National Cancer Institute (NCI), Hadassah Medical Organization, and The University of Texas Health Science Center, Houston.
There are two US patents protecting this investigational drug and twenty-two international patents.
Summary for Papaverine
| US Patents | 2,782 |
| International Patents | 22,088 |
| US Patent Applications | 4,325 |
| WIPO Patent Applications | 2,090 |
| Japanese Patent Applications | 15 |
| Clinical Trial Progress | Phase 3 (2019-04-01) |
| Vendors | 36 |
Recent Clinical Trials for Papaverine
| Title | Sponsor | Phase |
|---|---|---|
| Papaverine vs Heparin for Peripheral Arterial Catheter Patency in Pediatric Patients | The University of Texas Health Science Center, Houston | Phase 4 |
| Papaverine Hydrochloride and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer | National Cancer Institute (NCI) | Phase 1 |
| Papaverine Hydrochloride and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer | Ohio State University Comprehensive Cancer Center | Phase 1 |
Clinical Trial Summary for Papaverine
Top disease conditions for Papaverine
Top clinical trial sponsors for Papaverine
US Patents for Papaverine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Papaverine | Start Trial | Methods and compositions for treating infection | UNIVERSITY OF ROCHESTER (Rochester, NY) UNIVERSITY OF KANSAS (Lawrence, KS) | Start Trial |
| Papaverine | Start Trial | Implantable human liver tissue constructs and uses thereof | Massachusetts Institute of Technology (Cambridge, MA) | Start Trial |
| Papaverine | Start Trial | Cytochrome P450 fusion protein | The University of York (York, GB) Sun Pharmaceutical Industries (Australia) Pty Ltd (Notting Hill, Victoria, AU) | Start Trial |
| Papaverine | Start Trial | Matrix and layer compositions for protection of bioactives | Novus International, Inc. (St. Charles, MO) | Start Trial |
| Papaverine | Start Trial | Methods of inducing anesthesia | The Regents of the University of California (Oakland, CA) | Start Trial |
| Papaverine | Start Trial | Drug device configured for wireless communication | Pop Test Abuse Deterrent Technology, LLC (Cliffside Park, NJ) | Start Trial |
| Papaverine | Start Trial | Ultra-pure agonists of guanylate cyclase C, method of making and using same | SYNERGY PHARMACEUTICALS, INC. (New York, NY) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Papaverine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Papaverine | World Intellectual Property Organization (WIPO) | 2014052836 | 2032-09-27 | Start Trial |
| Papaverine | World Intellectual Property Organization (WIPO) | 2012048170 | 2030-10-06 | Start Trial |
| Papaverine | Australia | 2015261278 | 2034-05-16 | Start Trial |
| Papaverine | Canada | 2946812 | 2034-05-16 | Start Trial |
| Papaverine | European Patent Office | 3143125 | 2034-05-16 | Start Trial |
| Papaverine | United Kingdom | 201408729 | 2034-05-16 | Start Trial |
| Papaverine | United Kingdom | 201506805 | 2034-05-16 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
